4/8/2013

Astellas Pharma and Ambrx agreed to collaborate in the discovery and development of antibody-drug conjugates for cancer using the latter's site-specific conjugation technology, linkers and drug payloads. Ambrx will get $15 million upfront plus as much as $285 million in milestone fees and sales royalties. The rights to further develop and market the ADCs will go to Astellas.

Related Summaries